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Tankyrase promotes telomere elongation in human cells
Susan Smith* and Titia de Lange
Human telomeres are maintained by telomerase, a
reverse transcriptase that adds telomeric repeats to
chromosome ends [1,2]. In human tumors and
immortalized cells, telomeres are often maintained at a
constant length setting [3,4], indicating that
telomerase-mediated telomere elongation is tightly
regulated. Tankyrase, a telomeric poly(ADP-ribose)
polymerase (PARP) [5], was identified through its
interaction with TRF1 [6], a negative regulator of
telomere extension by telomerase [7]. Tankyrase-
mediated ADP-ribosylation inhibits binding of TRF1 to
telomeric repeats in vitro [5], suggesting that tankyrase
might regulate TRF1 and therefore control telomere
dynamics in vivo. Here, we present evidence that
tankyrase acts as a positive regulator of telomere
elongation in vivo, apparently by inhibiting TRF1.
Overexpression of tankyrase in the nucleus diminished
the level of unmodified TRF1 in immunoblots and led to
reduced immunofluorescence of TRF1 at interphase
telomeres. Long-term overexpression of tankyrase in
telomerase-positive human cells resulted in a gradual
and progressive elongation of telomeres. A PARP-
deficient form of tankyrase failed to affect TRF1 and did
not alter telomere length dynamics, consistent with
ADP-ribosylation of TRF1 as the main cause of altered
telomere homeostasis. Our results indicate that
tankyrase can induce telomere elongation in human
cells. We propose that tankyrase-mediated ADP-
ribosylation of TRF1 opens the telomeric complex,
allowing access to telomerase. 
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Results and discussion
To determine whether tankyrase influenced telomere
dynamics in vivo, we generated a version of tankyrase that
would be expected to exert its major effect in the nucleus.
Previous experiments indicated that, while a small fraction
of tankyrase localized to human telomeres in metaphase
spreads [5] and interphase cells [8], a substantial fraction
of the protein was found at other subcellular sites: nuclear-
pore complexes in interphase and centrosomes during
mitosis [8]. Tankyrase does not contain a nuclear localiza-
tion signal (NLS) and transfected tankyrase is excluded
from the nucleus unless it is co-transfected with TRF1
[8]. Therefore, we added an NLS to its amino terminus,
resulting in a protein that accumulated in the nucleus
(FN–tankyrase; Figure 1a; see below). In parallel, we gen-
erated a similarly tagged version of tankyrase with a
carboxy-terminal deletion that included the PARP and
sterile-alpha-module (SAM) domains, but retained the
TRF1-interaction domain (FN–tankyrase∆C; Figure 1a).
Both forms of tankyrase were stably expressed and
detectable in immunoblots (Figure 1b,c).
The effect of full-length and truncated tankyrase on the
accumulation of TRF1 on telomeres was determined by
transient transfection of HeLa1.2.11 cells, which afford
sensitive detection of telomeric proteins because of their
Figure 1
Tetracyclin-regulated expression of tankyrase proteins in HTC75 cells.
(a) Tankyrase constructs. F, FLAG epitope tag; N, NLS from SV40;
HPS, homopolymeric tracts of histidine, proline and serine.
(b,c) Immunoblot analysis of inducible tankyrase expression in HTC75
cells. (b) Four independent clonal cell lines, three expressing
FN–tankyrase (FN12, FN30, FN41) and, as a control, a fourth line that
does not express full-length FN–tankyrase (FN43). (c) Four independent
clonal cell lines expressing FN–tankyrase∆C (9N11, 9N25, 9N27,
9N34). Whole cell extracts from cultures grown in the presence
(uninduced) or absence (induced) of doxycyclin (dox) for 8 population
doublings (PDs) were probed with (b) anti-tankyrase antibody 465, anti-
poly(ADP-ribose) antibody 10H, anti-TRF1 antibody 371, or anti-TRF2
antibody 647, or (c) anti-FLAG antibody M2, or anti-TRF1 antibody 371.
The 9N27 lanes contain 50% less protein than the other cell lines.
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long telomeres [9]. Indirect immunofluorescence to detect
the FN–tankyrase in transfected cells showed that the
protein was predominantly nuclear (Figure 2a). Dual label-
ing of the same cells with anti-TRF1 antibody showed
that, in the tankyrase-overexpressing cells, TRF1 no
longer displayed a punctate pattern, suggesting that in
transfected cells TRF1 no longer accumulated at telom-
eres. We did not detect non-telomeric TRF1 in association
with the overexpressed tankyrase protein. Non-telomeric
TRF1 might be dispersed throughout the nucleus and
therefore difficult to detect, or the released protein might
be unstable. Additionally, the anti-TRF1 antibody might
not react with poly(ADP-ribosyl)ated TRF1 (see below).
Finally, we cannot rule out the possibility that poly(ADP-
ribosyl)ated TRF1 remains on telomeres, but is not
detected by TRF1 antibodies because of the modification.
This is unlikely, however, as poly(ADP-ribosyl)ation of
TRF1 in vitro inhibits its binding to telomeric DNA.
Overexpression of FN–tankyrase had no effect on the
staining pattern of the related telomeric-repeat-binding
protein TRF2 [10,11] (Figure 2b), consistent with the
specificity of tankyrase for TRF1 in vitro [5]. Comparison
of the localization patterns of FN–tankyrase and TRF2
indicated that they did not colocalize, suggesting that
FN–tankyrase did not reside at telomeres. Lack of telom-
eric accumulation for tankyrase would be expected if
TRF1, its binding partner, had been released from telom-
eres in transfected cells or was inhibited from binding to
telomeres. A similar loss of TRF1 from telomeres was noted
in HTC75 cell lines induced to express FN–tankyrase
(see below; data not shown). These observations indicated
that tankyrase can modulate the accumulation of TRF1,
but not TRF2, on telomeres in vivo.
The release of TRF1 from telomeres in response to over-
expression of tankyrase is likely to be due to the PARP
activity of the enzyme, as ADP-ribosylation of TRF1
inhibits its ability to form a stable complex with telomeric
DNA in vitro [5]. In contrast to the full-length protein,
expression of FN–tankyrase∆C had no detectable effect
on the distribution of TRF1 (Figure 2c). In fact,
FN–tankyrase∆C accumulated at telomeres, as evidenced
by its colocalization with TRF1. Inspection of cells express-
ing different amounts of the transfected protein suggested
that FN–tankyrase∆C localized to telomeres in a saturable
fashion; at low levels of expression, FN–tankyrase∆C
localized exclusively to telomeres, whereas at higher
expression levels the protein was also detectable through-
out the nucleoplasm. These observations are consistent
with FN–tankyrase∆C binding to and ultimately saturat-
ing the TRF1-binding sites at telomeres. FN–tankyrase∆C
(unlike FN–tankyrase) remained on telomeres, probably
because it was unable to ADP-ribosylate and therefore
release TRF1 and itself from telomeres. A similar colocaliza-
tion for TRF1 and FN–tankyrase∆C to telomeres was noted
in HTC75 cell lines induced to express FN–tankyrase∆C
(see below; data not shown). 
To examine the long-term effect of tankyrase on TRF1 and
telomere length homeostasis, we expressed tankyrase stably
in HTC75 cells. HTC75 is a telomerase-positive human
fibrosarcoma cell line that maintains telomeres at a stable
length setting [7]. This cell line contains the tetracycline-
controlled gene expression system, allowing controlled
analysis of changes in telomere length in response to
exogenous genes. Immunoblot analysis with anti-tankyrase
antibodies indicated doxycyclin-controlled expression of
FN–tankyrase in three stable clonal HTC75 cell lines,
FN12, FN30 and FN41 (Figure 1b). Probing with an anti-
poly(ADP-ribose) antibody revealed a diffuse signal that
coincided with induction of FN–tankyrase, but migrated
more slowly, consistent with the presence of poly(ADP-
ribosyl)ated FN–tankyrase [5] resulting from automodifi-
cation. The induction of FN–tankyrase was accompanied
by a reduction in TRF1 levels. We presume that this reduc-
tion is due to the generation of poly(ADP-ribosyl)ated
TRF1. We did not, however, detect modified forms of
TRF1 by immunoblot analysis. The modified forms of
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Figure 2
Tankyrase releases TRF1 from telomeres in a reaction that depends on
its PARP domain. Indirect immunofluorescence analysis of HeLa cells
transiently transfected with (a,b) FN–tankyrase or
(c) FN–tankyrase∆C. Cells were dually stained with (a–c) anti-FLAG
antibody M2 (green) and (a′,c′) anti-TRF1 antibody 371 (red) or
(b′) anti-TRF2 antibody 508 (red). (a′′–c′′) Superimposition of the red
and green images. DNA was stained with 4,6-diamidino-2-phenylindole
(DAPI, blue). The scale bar represents 5 µm.
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TRF1 might not react well with anti-TRF1 antibodies or
they might be unstable. Lack of detection of TRF1
could also result from the heterogeneous migration of
poly(ADP-ribosyl)ated forms [5], which might dilute the
signal below the level of detection. In contrast to TRF1,
the levels of TRF2 were unchanged by expression of
FN–tankyrase, consistent with the previous finding that
TRF1, but not TRF2, is ADP-ribosylated in vitro [5]. 
The reduction in TRF1 levels was likely to be due to
ADP-ribosylation of TRF1 by the overexpressed
FN–tankyrase. To test this directly, we generated HTC75
cells expressing the PARP-deficient form of FN–tankyrase,
FN–tankyrase∆C (Figure 1a). Immunoblot analysis with
anti-FLAG antibody indicated doxycyclin-controlled expres-
sion of FN–tankyrase∆C in four stable clonal cell lines,
9N11, 9N25, 9N27 and 9N34 (Figure 1c). In contrast to
the full-length protein, induction of FN–tankyrase∆C had
no detectable effect on the steady state level of TRF1
detected in immunoblots (Figure 1c).
To assess the effect of tankyrase expression on telomere
dynamics, the HTC75 cell lines were grown for over 100
PDs and the length of telomeric restriction fragments was
determined by standard genomic blotting. Previous
studies indicated that control HTC75 cell lines, trans-
fected with the empty vector, showed no change in telom-
ere length when grown for over 100 PDs in the presence
or absence of doxycyclin [7]. In contrast, the three cell
lines expressing FN–tankyrase showed a gradual and pro-
gressive increase in telomere length that was dependent
on doxycyclin (Figure 3a,b). The calculated increase in
telomere length in the absence of doxycyclin was 3.5 kb
for FN41 at PD 72, 4.8 kb for FN12 at PD 104, and 2.0 kb
for FN30 at PD 40. Telomeres showed progressive elon-
gation at similar rates of 48 bp (FN41), 46 bp (FN12), or
50 bp (FN30) per PD. In the presence of doxycyclin,
telomere length remained relatively constant, but did
become more heterogeneous, particularly in later PDs.
Although the three cell lines showed similar rates of elon-
gation, each displayed a unique pattern of elongation, sta-
bilization and, in one case, shortening. Immunoblot
analysis at PD 48 and 112 indicated that each of the cell
lines continued to express high levels of the transgene and
maintained a reduced level of TRF1 (Figure 3c). The
observed shortening and/or stabilization of telomere
length that occurred in the presence of transgene expres-
sion suggests the presence of an additional telomere
length regulation mechanism that is not directly affected
by the tankyrase expression. This additional mechanism
could depend on TRF2, which is also a regulator of telom-
ere maintenance [9] but is not affected by tankyrase. It is
not unlikely that each subclone of the HTC75 cell line
varies somewhat with regard to such additional pathways.
Minor variations in telomere length dynamics have also
been noted in an analysis of TRF1-mediated length
control [7].
The gradual elongation of telomeres in the cell lines
expressing FN–tankyrase is similar to the telomere elon-
gation induced by a dominant-negative allele of TRF1 [7]
and is consistent with perturbation of the telomerase-
mediated telomere maintenance pathway. Expression of
FN–tankyrase and reduction of TRF1 levels was not
accompanied by a notable change in telomerase activity as
detected in cell extracts using the TRAP assay (data not
shown), suggesting that tankyrase, like TRF1, does not
modulate telomere dynamics by a major direct effect on
telomerase activity detectable with the TRAP assay.
Brief Communication 1301
Figure 3
FN–tankyrase induces telomere lengthening. (a) Southern blot analysis
of HinfI/RsaI-digested genomic DNA from FN41 and FN12, which
express FN–tankyrase. Cell lines were grown for 104 PDs in the
presence (uninduced) or absence (induced) of doxycyclin and DNA
samples were analyzed at the indicated PDs. Blots were probed with a
TTAGGG-repeat probe to detect telomeric restriction fragments.
(b) Graphical presentation of telomere length changes in FN41, FN12
and FN30. Plots represent the mean telomere length values derived from
Southern blot analysis of cultures grown in the presence (uninduced;
triangles) or absence (induced; squares) of doxycyclin. (c) Immunoblot
analysis of whole cell extracts from cell lines (FN41, FN12 and FN30)
grown in the presence (uninduced) or absence (induced) of doxycyclin
for 8, 48 or 112 PDs. Blots were probed with anti-tankyrase antibody
465, anti-TRF1 antibody 371, or anti-TRF2 antibody 647.
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Telomere length was next assessed in HTC75 clones
expressing FN–tankyrase∆C. In contrast to cell lines
expressing the full-length protein, four cell lines express-
ing FN–tankyrase∆C showed no doxycyclin-dependent
telomere elongation (Figure 4a,b). Although telomere
length fluctuated, telomere length changes were not cor-
related with induction of the truncated tankyrase allele.
These results suggested that the carboxy-terminal PARP
domain was required for the telomere elongation induced
by FN–tankyrase. However, direct confirmation for the
role of this domain will require analysis of point mutations
in the PARP active site. Nonetheless, in contrast to the
FN–tankyrase cell lines, TRF1 was not detectably modi-
fied in the FN–tankyrase∆C lines (Figure 1c) or released
from telomeres (Figure 2c) and the telomeres did not
elongate (Figure 4a,b). These data are consistent with the
idea that tankyrase-induced telomere elongation is depen-
dent on ADP-ribosylation and concomitant release of
TRF1 from telomeres.
The data suggest that tankyrase can function as a positive
regulator of telomere length in vivo. It will be important to
determine whether tankyrase is required for telomerase-
mediated telomere maintenance, particularly in human
tumor cells. Recent studies indicate that inhibition of telom-
erase can limit growth of human cancer cells [12,13]. Thus,
tankyrase, which can be inhibited by small molecules [5],
holds promise as a target for anti-cancer therapies.
Supplementary material
Supplementary material including additional methodological detail is
available at http://current-biology.com/supmat/supmatin.htm.
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Figure 4
FN–tankyrase∆C does not induce telomere
lengthening. (a) Southern blot analysis of
Hinf I/RsaI-digested genomic DNA from four
clonal cell lines (9N11, 9N25, 9N27 and
9N34) expressing FN–tankyrase∆C. Cell lines
were grown in the presence (uninduced) or
absence (induced) of doxycyclin and DNA
samples were analyzed at the indicated PDs.
Blots were probed with a TTAGGG-repeat
probe to detect telomeric restriction
fragments. (b) Graphical presentation of
telomere length changes in clonal lines 9N11,
9N25, 9N27 and 9N34. Plots represent the
mean telomere length values derived from
Southern blot analysis of cultures grown in the
presence (uninduced; triangles) or absence
(induced; squares) of doxycyclin.
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